Friday, 16 October 2026European Markets

SOGN SPAREBANK And B2HOLDING Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(VIANEWS) - SOGN SPAREBANK (SOGN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Financial Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SOGN SPAREBANK (SOGN.OL) kr151.00 6.54% 7.47%
B2HOLDING (B2H.OL) kr6.95 3.02% 6.02%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SOGN SPAREBANK (SOGN.OL)

6.54% Forward Dividend Yield and 7.47% Return On Equity

Sogn Sparebank provides various banking products and services in Norway. The company offers savings products; home loans and small loans, as well as loans for cars and other vehicles; credit and other cards; and mobile and online banking services. It also provides bank guarantees, construction loans, overdraft, and business loans, as well as leasing and securities trading services. In addition, the company offers home and leisure, animals, damage, car, liability, work machine, data attack, farm building, operating equipment and crop, property damage, health, homeowners, agriculture, craftsman, commercial vehicle, business, and personnel insurance products. Sogn Sparebank was founded in 1846 and is based in Årdalstangen, Norway.

Earnings Per Share

As for profitability, SOGN SPAREBANK has a trailing twelve months EPS of kr32.77.

PE Ratio

SOGN SPAREBANK has a trailing twelve months price to earnings ratio of 4.61. Meaning, the purchaser of the share is investing kr4.61 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.47%.

More news about SOGN SPAREBANK.

2. B2HOLDING (B2H.OL)

3.02% Forward Dividend Yield and 6.02% Return On Equity

B2Holding ASA, together with its subsidiaries, provides debt solutions for banks and institutional vendors. The company's portfolio of business consists of purchase, management, and collection of unsecured and secured non-performing loans. Its services include debt purchase and collection, credit information, third party debt collection, and consumer lending, as well as telemarketing and fraud prevention services. It principally operates in Norway, Sweden, Denmark, Finland, Estonia, Latvia, Lithuania, Poland, Croatia, Slovenia, Serbia, Montenegro, Bosnia and Herzegovina, Austria, the Czech Republic, Hungary, Spain, Italy, France, Bulgaria, Romania, Greece, and Cyprus. B2Holding SAS was incorporated in 2008 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, B2HOLDING has a trailing twelve months EPS of kr1.18.

PE Ratio

B2HOLDING has a trailing twelve months price to earnings ratio of 5.89. Meaning, the purchaser of the share is investing kr5.89 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.02%.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter is 316.7% and a drop 30.6% for the next.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on May 26, 2023, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 3.02%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 5.3%, now sitting on 2.83B for the twelve trailing months.

Moving Average

B2HOLDING's value is above its 50-day moving average of kr6.90 and below its 200-day moving average of kr7.50.

More news about B2HOLDING.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com